跳至主要内容
临床试验/NCT06652360
NCT06652360已完成不适用

A Pilot Study to Investigate the Relative Effectiveness and Safety of Chemical Wound Debridement and Curettage in the Treatment of Venous and Mixed Aetiology Leg Ulcers.

DEBx Medical B.V.1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年11月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80
试验地点
1
主要终点
Wound surface

研究概览

简要总结

A pilot study to investigate the relative effectiveness and safety of chemical wound debridement and curettage in the treatment of venous and mixed aetiology leg ulcers.

详细描述

A pilot study to investigate the relative effectiveness and safety of chemical wound debridement versus the curettage wound debridement in the treatment of venous and mixed aetiology leg ulcers in the United Kingdom

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants with a venous leg ulcer or mixed aetiology ulcer.
  • Duration of wound ≥ 6 weeks ≤ 5 years
  • Wound is ≥ 5 cm2 ≤ 200cm2
  • Presence of at least 25% visible slough within the wound bed
  • The Participant must be able to understand the study and provide written informed consent
  • No clinical signs of infection

排除标准

  • Known hypersensitivity or contraindications to any of the wound treatments, dressings or compression bandaging to be used in the trial
  • Current local or systemic antibiotics in the week prior to inclusion
  • Clinically infected wound as determined by the presence of 3 or more of the following clinical signs: perilesional erythema, pain between two dressing changes, malodorous wound, abundant exudate and oedema
  • Prolonged treatment with immunosuppressive agents or high dose corticosteroids
  • Participants who have a current illness or condition which may interfere with wound healing in the last 30 days (carcinoma, connective tissue disease, autoimmune disease or alcohol or drug abuse)
  • Participants who have participated in a clinical trial on wound healing within the past month
  • Participants with a known history of non- adherence with medical treatment

研究组 & 干预措施

Chemical Debridement

Active Comparator

1 single treatment of chemical debridement will be applied in this arm at initiation visit. No repeated treatment done in this trial

干预措施: Chemical Debridement (Device)

Sharp debridement

Active Comparator

In the control arm wound debridement by curettage will be performed at initiation visit and after 2 weeks when clinician deems this necessary, conform standard of care protocol

干预措施: Curettage debridement (Device)

结局指标

主要结局

Wound surface

时间窗: 12 weeks

Change in wound surface area (cm\^2)

Wound Debris

时间窗: 12 weeks

Change in the percentage of the wound bed covered with slough

次要结局

  • Wound healing(12 weeks)
  • Quality of Life(12 weeks)
  • Patient Comfort in treatment process(12 weeks)
  • Device Safety(12 weeks)
  • Treatment Comfort in performance and acceptance(12 weeks)
  • wound condition(12 weeks)

研究者

发起方
DEBx Medical B.V.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验